Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Compass Therapeutics, Inc. is reported as the issuer of common stock held by several Vivo Opportunity investment entities. Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC each report beneficial ownership of 7,207,573 shares of common stock, representing 4.0% of the class. Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC each report beneficial ownership of 549,487 shares, or 0.3% of the class. These ownership percentages are based on 180,087,915 shares of common stock outstanding as of July 28, 2026. Each reporting person has sole voting and sole dispositive power over its respective shares and reports ownership of 5% or less of the class.
Key Figures
Shares beneficially owned (Vivo Opportunity Fund Holdings, L.P.):7,207,573 sharesPercent of class (Vivo Opportunity Fund entities):4.0%Shares beneficially owned (Vivo Opportunity Cayman Fund, L.P.):549,487 shares+2 more
5 metrics
Shares beneficially owned (Vivo Opportunity Fund Holdings, L.P.)7,207,573 sharesCompass Therapeutics common stock; beneficial ownership reported by Vivo Opportunity Fund Holdings, L.P.
Percent of class (Vivo Opportunity Fund entities)4.0%Ownership percentage of Compass Therapeutics common stock reported by Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC
Shares beneficially owned (Vivo Opportunity Cayman Fund, L.P.)549,487 sharesCompass Therapeutics common stock; beneficial ownership reported by Vivo Opportunity Cayman Fund, L.P.
Percent of class (Vivo Opportunity Cayman entities)0.3%Ownership percentage of Compass Therapeutics common stock reported by Vivo Opportunity Cayman Fund, L.P. and Vivo Opportunity Cayman, LLC
Shares outstanding180,087,915 sharesCompass Therapeutics common stock outstanding as of July 28, 2026, used to calculate ownership percentages
Key Terms
beneficially owns, sole voting power, sole dispositive power, percent of class, +1 more
5 terms
beneficially ownsfinancial
"Vivo Opportunity, LLC beneficially owns 7,207,573 shares of Common Stock."
Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.
sole voting powerfinancial
"5 | Sole Voting Power 7,207,573.00 6 | Shared Voting Power 0.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
sole dispositive powerfinancial
"7 | Sole Dispositive Power 7,207,573.00 8 | Shared Dispositive Power 0.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
percent of classfinancial
"The percentage of class is based on 180,087,915 shares of Common Stock outstanding"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
limited partnershipfinancial
"Vivo Opportunity Fund Holdings, L.P. is a Delaware limited partnership."
A limited partnership is a legal business structure with two types of partners: at least one general partner who runs the business and bears full legal responsibility, and one or more limited partners who contribute money, share profits, and have liability capped at their investment. For investors, it matters because it separates control from financial exposure — like putting money into a store without managing it — and affects how returns, risks, taxes and transferability of ownership are handled.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of Compass Therapeutics (CMPX) does Vivo Opportunity Fund Holdings, L.P. own?
Vivo Opportunity Fund Holdings, L.P. beneficially owns 7,207,573 shares of Compass Therapeutics common stock, representing 4.0% of the outstanding class, based on 180,087,915 shares outstanding as of July 28, 2026.
How many Compass Therapeutics (CMPX) shares does Vivo Opportunity Cayman Fund, L.P. hold?
Vivo Opportunity Cayman Fund, L.P. beneficially owns 549,487 shares of Compass Therapeutics common stock, which represents 0.3% of the class, calculated using 180,087,915 shares outstanding as of July 28, 2026.
What is the total Compass Therapeutics (CMPX) share count used to calculate Vivo’s ownership?
The ownership percentages for the Vivo entities are calculated using 180,087,915 shares of Compass Therapeutics common stock outstanding as of July 28, 2026, as reported in the company’s Form 10-Q filed on August 6, 2026.
Do the Vivo Opportunity entities share voting power over Compass Therapeutics (CMPX) shares?
Each Vivo entity reports sole voting power and sole dispositive power over its respective Compass Therapeutics shares, and no shared voting or dispositive power is reported for any of the positions.
Why do Vivo Opportunity entities report ownership of 5 percent or less of Compass Therapeutics (CMPX)?
Each reporting Vivo entity discloses ownership of 4.0% or 0.3% of Compass Therapeutics common stock, so each individually holds 5 percent or less of the class, as reflected in the ownership-of-5-percent-or-less disclosure.
Who controls the Compass Therapeutics (CMPX) shares held by the Vivo limited partnerships?
The shares of Compass Therapeutics held by Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P. are controlled by their respective general partners, Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC, which each report matching beneficial ownership and powers.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Compass Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
20454B104
(CUSIP Number)
06/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
20454B104
1
Names of Reporting Persons
Vivo Opportunity Fund Holdings, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
7,207,573.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
7,207,573.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,207,573.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.0 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The number represents shares of common stock, par value $0.0001 per share (the "Common Stock") of Compass Therapeutics, Inc. (the "Issuer") held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
The percentage of class is based on 180,087,915 shares of Common Stock outstanding, as of July 28, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on August 6, 2026.
SCHEDULE 13G
CUSIP Number(s):
20454B104
1
Names of Reporting Persons
Vivo Opportunity, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
7,207,573.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
7,207,573.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,207,573.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
4.0 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
The percentage of class is based on 180,087,915 shares of Common Stock outstanding, as of July 28, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.
SCHEDULE 13G
CUSIP Number(s):
20454B104
1
Names of Reporting Persons
Vivo Opportunity Cayman Fund, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
549,487.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
549,487.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
549,487.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.3 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.
The percentage of class is based on 180,087,915 shares of Common Stock outstanding, as of July 28, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.
SCHEDULE 13G
CUSIP Number(s):
20454B104
1
Names of Reporting Persons
Vivo Opportunity Cayman, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
CAYMAN ISLANDS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
549,487.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
549,487.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
549,487.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
0.3 %
12
Type of Reporting Person (See Instructions)
OO
Comment for Type of Reporting Person: The number represents shares of Common Stock of the Issuer held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.
The percentage of class is based on 180,087,915 shares of Common Stock outstanding, as of July 28, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Compass Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
80 Guest St., Suite 601, Boston, Massachusetts, 02135
Item 2.
(a)
Name of person filing:
Vivo Opportunity Fund Holdings, L.P. and its General Partner Vivo Opportunity, LLC
Vivo Opportunity Cayman Fund, L.P. and its General Partner Vivo Opportunity Cayman, LLC
(b)
Address or principal business office or, if none, residence:
192 Lytton Avenue, Palo Alto, CA 94301
(c)
Citizenship:
Vivo Opportunity Fund Holdings, L.P. is a Delaware limited partnership.
Vivo Opportunity, LLC is a Delaware limited liability company.
Vivo Opportunity Cayman Fund, L.P. is a Cayman Islands limited partnership.
Vivo Opportunity Cayman, LLC is a Cayman Islands limited liability company.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
20454B104
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
Vivo Opportunity, LLC beneficially owns 7,207,573 shares of Common Stock. The securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P.
Vivo Opportunity Cayman, LLC beneficially owns 549,487 shares of Common Stock. The securities are held of record by Vivo Opportunity Cayman Fund, L.P. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P.
(b)
Percent of class:
Vivo Opportunity Fund Holdings, L.P.: 4.0%
Vivo Opportunity, LLC: 4.0%
Vivo Opportunity Cayman Fund, L.P.: 0.3%
Vivo Opportunity Cayman, LLC.: 0.3 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
Vivo Opportunity Fund Holdings, L.P.: 7,207,573 shares
Vivo Opportunity, LLC: 7,207,573 shares
Vivo Opportunity Cayman Fund, L.P.: 549,487 shares
Vivo Opportunity Cayman, LLC: 549,487 shares
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
Vivo Opportunity Fund Holdings, L.P.: 7,207,573 shares
Vivo Opportunity, LLC: 7,207,573 shares
Vivo Opportunity Cayman Fund, L.P.: 549,487 shares
Vivo Opportunity Cayman, LLC: 549,487 shares
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Vivo Opportunity Fund Holdings, L.P.
Signature:
/s/ Kevin Dai
Name/Title:
Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner
Date:
08/14/2026
Vivo Opportunity, LLC
Signature:
/s/ Kevin Dai
Name/Title:
Kevin Dai/Managing Member
Date:
08/14/2026
Vivo Opportunity Cayman Fund, L.P.
Signature:
/s/ Kevin Dai
Name/Title:
Kevin Dai/Managing Member of Vivo Opportunity Cayman, LLC, General Partner
